Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Cash from Operations (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Cash from Operations data on record, last reported at 21093000.0 in Q4 2020.

  • For Q4 2020, Cash from Operations fell 137.86% year-over-year to 21093000.0; the TTM value through Dec 2020 reached 60811000.0, changed N/A, while the annual FY2024 figure was 67705000.0, 45.6% up from the prior year.
  • Cash from Operations reached 21093000.0 in Q4 2020 per KLRS's latest filing, down from 18057000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 6403000.0 in Q3 2019 and bottomed at 21093000.0 in Q4 2020.